Nifuroxazide is a nitrofuran compound inhibitor of STAT transcription factor signaling. Nifuroxazide is described to block constitutive phosphorylation of STAT3 by reducing Jak kinase autophosphorylation, decreasing the viability of myeloma cells depending on constitutive STAT3 activity for survival while not affecting normal peripheral blood mononuclear cells. Nifuroxazide produces decreases in tyrosine phosphorylation of Jak2 and Tyk2, and showed no effects on EGF receptor tyrosine kinase or Src kinase, indicating a relative specificity of Nifuroxazide for Jak2 and Tyk2. Nifuroxazide shows no inhibition of Akt or MAPK phosphorylation.
1. Nelson, E.A., et al. 2008. Blood. 112: 5095-5102. PMID: 18824601
Vedi quanti altri hanno usato Nifuroxazide (CAS 965-52-6). Clicca sulla voce per laccesso a PubMed .
PMID: # 28949055 Osabe, M. et al. 2017. J Appl Toxicol.
PMID: # 26136413 Matsuo, Y. et al. 2015. Journal of cachexia, sarcopenia and muscle. 6: 62-72.
PMID: # 23095323 Jiang, X. et al. 2013. Clinical cancer research : an official journal of the American Association for Cancer Research. 19: 598-609.
PMID: # 18824601 Nelson, EA. et al. 2008. Blood. 112: 5095-5102.